Quarterly report pursuant to Section 13 or 15(d)

Note 1 - Corporate Information (Details Textual)

v3.24.3
Note 1 - Corporate Information (Details Textual)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Jul. 18, 2023
Sep. 30, 2024
USD ($)
$ / shares
Sep. 30, 2023
USD ($)
Sep. 30, 2024
USD ($)
$ / shares
Sep. 30, 2023
USD ($)
Dec. 31, 2023
USD ($)
$ / shares
Aug. 07, 2024
$ / shares
Mar. 27, 2024
USD ($)
May 31, 2013
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares   $ 0.001   $ 0.001   $ 0.001      
Cash, Cash Equivalents, and Short-Term Investments   $ 19,400   $ 19,400          
Net Income (Loss) Attributable to Parent   (2,887) $ (10,752) (11,369) $ (19,959)        
Retained Earnings (Accumulated Deficit)   (326,333)   (326,333)   $ (314,964)      
Series F Preferred Stock [Member]                  
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares             $ 0.01    
Preferred Stock, Voting Rights, Number of Votes Per Share             25,000,000    
Series F Preferred Stock [Member] | Board of Directors Chairman [Member]                  
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares             $ 0.001    
Shares Issued, Price Per Share (in dollars per share) | $ / shares             $ 1    
B P Assets X I I Inc [Member] | License [Member] | Exclusive Product License Agreement [Member] | Phase 2 Trials [Member]                  
Contracts Receivable, Claims and Uncertain Amounts               $ 15,000  
B P Assets X I I Inc [Member] | License [Member] | Exclusive Product License Agreement [Member] | Pivotal Clinical Trials [Member]                  
Contracts Receivable, Claims and Uncertain Amounts               $ 40,000  
Severance and Benefits Costs [Member]                  
Restructuring and Related Cost, Number of Positions Eliminated, Period Percent 70.00%                
Restructuring and Related Cost, Cost Incurred to Date           7,500      
Severance Costs           $ 2,400      
Restructuring and Related Cost, Expected Cost Remaining   $ 4,300   $ 4,300          
Pieris Pharmaceuticals GmbH [Member]                  
Business Acquisition, Percentage of Voting Interests Acquired                 100.00%